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Abstract
Multiple sclerosis is a relapsing and eventually progressive disorder of the 
central nervous system that continues to challenge researchers who try to under-
stand the pathogenesis of the disease and prevent its progression. Interferon-beta is 
the most widely prescribed treatment for MS. Peripheral blood seems to mirror the 
immunological disturbances that underlie MS, which could represent the migration 
patterns between periphery and other tissues according to the clinical phase of the 
disease. Based on this assumption, several studies point to significant alterations in 
peripheral blood homeostasis of different subpopulations of T cells, like γδ T cells 
or Th1, Th2 and Th17 functional subsets; of B cells subpopulations; and of innate 
cells like monocytes and dendritic cells. The main goal of this chapter is to make 
an in-depth review of the major findings described in the literature that correlate 
specific alterations on different leukocytes subpopulations with disease status, and 
which therefore have the potential to constitute a peripheral biomarker of disease 
progression.
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1. Introduction
Around 2.8 million people are diagnosed with multiple sclerosis (MS) world-
wide. MS is an autoimmune demyelinating disease of the central nervous system 
(CNS) of unknown etiology. Hallmarks of MS include focal inflammatory infil-
trates, demyelinating plaques, reactive gliosis, and axonal damage [1, 2].
The mechanism of MS pathology involves complex interactions between systems 
and cell types including neurons, glia, and immune cells, accompanied by perme-
ability of the blood–brain barrier (BBB). Autoreactive T cells activated outside the 
CNS cross the BBB and are reactivated by local antigen-presenting cells. Secretion 
of proinflammatory cytokines stimulates microglial cells and astrocytes, recruits 
additional inflammatory cells, and induces antibody production by plasma cells [3].
Recombinant interferon-β (IFN-β) remains the most widely prescribed treat-
ment for relapsing–remitting MS (RRMS) and a valid approach because of its good 
benefit/risk profile. Despite widespread use of IFN-β, its therapeutic mechanism 
is still partially understood. The efficacy of IFN-β treatment has been shown by 
a decreased annual relapse rate, disability progression and inflammatory brain 
lesions resulting in the approval of different IFN-β preparations [4].
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IFN-β is a highly pleiotropic cytokine which antagonizes the proinflammatory 
milieu by inhibiting expression of proinflammatory molecules, while increasing 
production of anti-inflammatory factors. It inhibits leukocyte trafficking, regulates 
the adhesion molecule expression and inhibits matrix metalloproteinase activity. 
The mechanism of action of IFN-β is complex and multifactorial but has been 
shown to reduce the biological activity of RRMS in several clinical class I trials [5].
The identification of peripheral markers that could reflect the clinical course 
of MS and the efficacy of treatment is a stimulating field of research and debate. 
An ideal biomarker is characterized by high sensitivity and specificity as well as a 
simple, cost effective, reproducible, and non-invasive detection method [6]. For 
instance, there are reports focusing molecules and autoantibodies as potential 
biomarkers in the MS disease course. Our focus in this chapter is on circulating 
leucocytes that can be considered during the follow of RRMS patients in remission 
versus relapse phase.
2. Multiple sclerosis
MS is an autoimmune disease of the brain and the spinal cord characterized by 
chronic inflammation, demyelination, gliosis and neuronal loss. The demyelination 
consists of the damage of the myelin sheath surrounding nerves, consequently 
affects the function of the nerves. The pathological hallmark of chronic MS is the 
demyelinated plaque or lesions, which consists of a well-demarcated hypocel-
lular area characterized by the loss of myelin sheaths or oligodendrocytes, relative 
preservation of axons, and the formation of astrocytic scars [1].
The etiology of MS remains elusive, with a complex multifactorial system impli-
cated, in which environmental factors are hypothesized as interacting with geneti-
cally susceptible individuals. MS causes a heterogeneous array of symptoms and 
signs because of the differential involvement of motor, sensory, visual and autonomic 
systems with serious physical disability in young adults, especially women [2, 4, 7].
The CNS is frequently described as an immune-privileged site, evidence sup-
ports the notion that the CNS receives limited immune surveillance by peripheral 
lymphocytes under physiological conditions. New findings provide a mechanism 
by which large particles and immune cells can drain from the brain and interface 
directly with the peripheral immune system [8, 9].
MS is triggered in the periphery or in the CNS. The CNS-extrinsic (peripheral) 
model is the most widely accepted and is consistent with the method used to induce 
experimental autoimmune encephalomyelitis (EAE), the animal model for neuro-
inflammation. The autoreactive T cells from MS patients may become activated in 
the periphery as a result of a molecular mimicry, gain access to the CNS, and T cells 
generated against non-self-epitopes (viral or microbial antigens) cross-react with 
self-myelin epitopes of similar sequence [10–12].
85% of patients present a RR form of MS, characterized by discrete episodes of 
neurological dysfunction (relapses) separated by clinical stable periods with lack of 
disease progression (remissions). More than 30% remain in the RRMS form of the 
disease into old age [7, 11–13].
Relapse is the clinical result of an acute inflammatory focal lesion and is typically 
discernible using magnetic resonance imaging. Relapse is defined as newly appear-
ing neurological symptoms in the absence of fever or infections that last for more 
than 24 hours and are separated from the previous event by at least one month. The 
frequency of relapses can vary widely among patients as well as during different 
periods during an individual patient’s disease. The relapse tends to be present for a 
limited time – days or weeks – and can lead to full recovery or can leave sequelae. 
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At present time, no clinical features or biomarkers that are predictive of relapse 
rates have been identified. The signs and symptoms that occur during relapses are 
also diverse and unpredictable [3, 8, 11].
Immunological characteristics of MS lesions have been reflected in circulating 
immune cells of MS patients. Peripheral blood provides a ‘window’ into the immu-
nopathogenesis of MS. The immunological disturbances that underlie MS can be 
observed not only in the CNS, but also through examination of peripheral immune 
cells [14].
3. Therapeutic management
IFN-β and glatiramer acetate have been used as first-line disease-modifying 
therapy for RRMS. More than two decades have passed since IFN-β was found to be 
effective in the management of MS. IFN-β treatment efficacy has been shown by a 
decrease in the annual relapse rate, in disability progression and in inflammatory 
brain lesions, resulting in the approval of different IFN-β preparations [15–17].
IFNs are naturally occurring cytokines, secreted by various cells such as fibro-
blasts, NK cells, leukocytes, and epithelial cells in response to pathogens such as 
bacteria, viruses, parasites, and tumor cells, as well as other foreign substances. 
They have a wide range in anti-inflammatory processes, regulation of cell growth 
and modulation of immune responses [18, 19].
IFN-β binds to the interferon receptor, activates the Janus kinase/signal transducer 
and the activator of transcription (STAT) pathway to phosphorylate STAT1 and 
STAT2. The activation of interferon-stimulated genes leads to the production of anti-
viral, antiproliferative, and antitumour products. The effectiveness of IFN-β in the 
treatment of MS may rely on both anti-viral and immunomodulatory aspects [26, 27].
IFN-β was the first immunomodulatory therapy approved by the U.S. Food and 
Drug Administration and is the most widely prescribed treatment for MS; it is 
generally well tolerated and overall reduces the relapse rate by 30% in patients with 
RRMS [4].
Several IFN-β preparations have been approved with differing structures 
(glycosylated IFN-β-1a vs. non-glycosylated IFN-β-1b), formulation (lyophilized 
vs. liquid), used excipients (e.g., containing serum albumin or not), modification 
(pegylation), dosage (protein load and bioactivity), route of administration (sub-
cutaneous vs. intramuscular), or frequency of injection (ranging from bi-weekly to 
every other day). IFN-β shows high tissue distribution; however, it is not supposed 
to cross the BBB and exerts its immunomodulatory mechanism in the peripheral 
compartment. IFN-β is cleared via renal and hepatic pathways, in which catabolism 
seems to be important rather than simple excretion [15].
The therapeutic benefit of IFN-β in MS has been proven in several large clinical 
trials, with the effect of IFN-β therapy being more studied on T and B cells [20]. 
In spite of this, it is known that the biological functions of IFN-β act in both innate 
and adaptive immune responses and may influence phenotype and functions of all 
MS-relevant immune cells [21].
4.  Peripheral blood leukocytes as potential biomarkers of disease 
activity
A biomarker is defined as a characteristic that can be objectively measured 
and evaluated and serves as an indicator of normal biological processes, patho-
logical processes or pharmacological reactions to therapy. An ideal biomarker is 
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characterized by high sensitivity and specificity as well as a simple, cost effective, 
reproducible, and non-invasive detection method [6].
In this section we synthesize and integrate the most relevant data regarding 
the characteristics of the selected immune cells that could be considered as IFN-β 
treatment-related biomarkers. The main goal of this work is an attempt to help 
researchers to perform a good assessment of immune cells in future studies. The 
presented data is a result of a compilation of several studies and findings.
4.1 Antigen-presenting cells
Antigen presenting cells (APCs) are considered key players in the immune 
surveillance of CNS and, at the same time, they are critically involved in the 
pathogenesis of CNS autoimmune diseases. They are a morphologically and 
functionally diverse group of cells that links the innate and adaptive immune 
responses. These cells are specialized in the presentation of antigens to lympho-
cytes, particularly T cells. Included among such cells are dendritic cells (DCs), 
monocytes and macrophages (derived from monocytes that migrated from the 
blood stream to tissues). B lymphocytes that specifically capture antigens via 
their clonally expressed membrane immunoglobulin can also function efficiently 
as APCs to T cells [22].
4.1.1 Dendritic cells
In humans, DCs comprise two major subsets: plasmacytoid DCs (pDCs) and 
myeloid (mDCs). Through nucleic acid-sensing, pDCs activate toll-like receptors 
(TLR), such as TLR7 and TLR9, rapidly producing type I IFN. mDCs are dedicated 
APCs that have a characteristic dendritic morphology, express high levels of MHC 
class II molecules and recognize pathogen-derived lipids, proteins and nucleic-acids 
by TLR2, TLR4 and TLR3 respectively [23].
The DCs subsets may be helpful as biomarker between remission and relapse of 
RRMS patients treated with IFN-β. The circulating mDCs subset reduces in remis-
sion and increase in relapse RRMS patients. On the other hand, the pDCs frequency 
are maintain across the different phases of disease. Usually, these subsets present a 
low frequency in systemic circulation, so the mDCs/pDCs ratio is a good represen-
tative of the alteration observed in the DCs subsets. The mDCs/pDCs decreases in 
remission RRMS patients and is re-established in relapse RRMS patients, constitut-
ing a potential peripheral biomarker [24, 25].
The involvement of DCs in MS arises from studies that demonstrate the abun-
dant presence of these cells in the inflamed CNS lesions and in the CSF of MS 
patients [21].
One of the immunomodulatory effects of IFN-β in the EAE model is the 
reduction in antigen presentation, particularly myelin-specific antigens, leading 
to reduced T-cell responses [23, 30]. In contrast with these effects, in remission 
phase it was observed that the DCs subsets increase the expression of HLA-DR 
and decrease in the relapse phase. The variation in HLA-DR expression is more 
evident in the mDCs subset. The same subset reduce the mRNA gene expression of 
CX3CR1; fractalkine is known to be upregulated and released in response to pro-
inflammatory stimuli and induces adhesion, chemoattraction, and activation of 
leukocytes [25].
The activation status of the mDCs subset could discriminate between RRMS 
phases. This subset shown a highest activated status in remission than in relapse 
phase, through the increased HLA-DR expression and a reduced migratory capabil-
ity, since reduce the mRNA gene expression of CX3CR1.
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4.1.2 Monocytes
Monocytes represent a heterogeneous population of primary immune effector 
cells with distinct phenotypical and functional characteristics; their differential 
roles in steady-state immune surveillance and the pathogenesis of human CNS 
disease are poorly understood [26].
The differential expression of CD14 (part of the receptor for lipopolysaccha-
ride) and CD16 (also known as FcγRIII) allows monocytes to be segregated into 
three subsets. The major subset designated “classical” monocytes (CD14++CD16−, 
cMo), corresponds to 80–90% of circulating monocytes. CD16 expressing mono-
cytes are divided into a named “intermediate” monocyte (CD14++CD16+, iMo) and a 
subset classified as “non-classical” monocytes (CD14+CD16++, ncMo); each of these 
subsets corresponds to 5–10% of circulating monocytes [27, 28].
Patients with MS display high levels of monocyte-secreted inflammatory mol-
ecules in serum compared to healthy individuals, demonstrating a role for periph-
eral monocytes in the progression of the disease. Increased levels of serum tumor 
necrosis factor (TNF) α and β have been reported in MS relapse. Monocytes and 
microglia are known to act as major effectors in the demyelinating process through 
direct interaction and the production of proinflammatory cytokines and mediators 
(e.g., IL-1b, nitric oxide). CD16+ monocytes may contribute to the breakdown of 
the BBB by facilitating T cell trafficking into the CNS [22, 26, 29].
Research performed on monocyte pool in RRMS patients is scarce and ambigu-
ous. A recent work achieved a significant decrease of the ncMo subset in both 
phases of RRMS patients, although in a higher extension in remission patients [25].
The frequency of monocytes subsets does not allow us to identify different 
phases of RRMS, but the HLA-DR expression could constitute a potential important 
biomarker between remission and relapse phases. A significant increase in HLA-DR 
expression in all monocyte subsets in the remission group when compared with 
healthy and relapse groups, has been described [25]. IFN-β enhances HLA-DR expres-
sion in circulating monocytes, but inside the CNS, one prominent model is based on 
the observation that IFN-β inhibits the IFNγ upregulation of MHC class II molecules 
on cell surface of macrophages and glial cells and therefore diminishes antigen 
presentation [30]. In the periphery, Kantor et al. report that the increase of MHC Class 
II expression in monocytes induced by IFN-β may contribute to the positive immuno-
modulatory effect in MS [31]. These findings were reinforced by the observation that 
when IFN-β-stimulated monocytes were used to stimulate autologous T cells, there 
was an increased secretion of anti-inflammatory cytokine IL-13 [32].
4.2 T cells
4.2.1 CD4+ and CD8+ T cells
T cells are central regulators of the adaptive immune response, they help B lym-
phocytes to produce antibodies and secrete cytokines that provide efficient protec-
tion against pathogens. Distinct T helper (Th) cell subsets, producing one or more 
lineage-defining cytokines and expressing master transcription factors and homing 
receptors. Th subsets are differentiated from naive CD4+ T cells in response to a 
specific class of pathogenic microorganisms and to the cytokine milieu. This occurs 
in peripheral lymph nodes by mature DCs that present pathogen-derived peptides 
associated to MHC class II. With the involvement of their costimulatory molecules, 
DCs promote T cell proliferation and produce polarizing cytokines. In turn T cell 
was differentiated in distinct Th cell subsets, such as Th1, Th2, Th17, regulatory T 
(T reg) and T follicular helper (Tfh) [33].
Neuroimmunology
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The CD4+ T cells have been the most studied in the pathogenesis of MS, although 
CD8+ T cells are the dominant lymphocyte population in all stages of disease and 
lesions of MS patients. Naive CD8+ T cells follow a similar differentiation pro-
gramme of CD4+ T cells [34, 35].
Th1 cells are described as being the pathogenic subset of T cells, whereas Th2 
cells are reported to exert inhibitory effects [5]. Previous studies have pointed to a 
reduction in pro-inflammatory capability promoted by IFN-β therapy, consisting 
of a reduction of the expression of Th1-induced cytokines while enhancing Th2 
responses [18]. Concerning the T cytotoxic (Tc) subsets, it has been reported the 
same behavior, in remission a downregulation of pro-inflammatory Tc1 responses 
and up-regulation of anti-inflammatory Tc2 with a beneficial effect on disease 
activity [36]. This dichotomy Th1, Th2 subsets and Tc1, Tc2 subsets could contrib-
ute to discriminate between remission and relapse phases.
The identification of Th17 cells helped to resolve some in adequacies of the 
original Th1/Th2 concept that had dominated T cell immunology research filed for 
almost 20 years. For a long time, it was thought that the IL-12/IFNγ pathway and 
Th1 cells were central to the development of autoimmune disease [37].
Both Th1 and Th17 cells have been implicated in the initiation and progression 
of disease in RRMS and its experimental model EAE [19]. The link between Th17 
cells, IL-17 and MS relapses comes from the observation that in humans, Th17 cells 
are able to cross the BBB in MS lesions, enhancing neuroinflammation. In vitro 
studies have revealed that IL-17 blocks the differentiation and reduces the survival 
of oligodendrocyte lineage cells. In EAE model, it has been suggested that Th17 cells 
interact directly with neurons, forming antigen-independent, immune, synapse-
like contacts [7, 38].
It is assumed that the inhibition of Th17 cells in RRMS patients attenuates the 
disease, however conflicting data have been published. Axtell et al. reported that 
IFN-β treatment effectively blocked disease symptoms in mice with EAE induced 
with Th1 cells. Otherwise, in EAE induced with Th17 cells the IFN-β treatment 
worsened disease [19].
In RRMS patients, it is not clear whether a more specific blockade of the Th17 
pathway has beneficial effects in MS patients. Treatment with an antibody directed 
against IL-12p40 and therefore neutralizing both IL-12 and IL-23 did not result in a 
significant reduction of disease activity [39].
A meta-analysis pointed out several limitations across studies that assess the lev-
els of peripheral Th17 cells and serum Th17-related cytokines. Like the severities of 
the disease and clinical subtypes in MS patients; the disease duration from relapse; 
and that the MS treatments were not consistent; and it was postulated that most 
studies selected MS patients with high disease activity. There were differences in 
experimental methods between studies and a lack of detailed standardized methods 
to identify the Th17 cells and Th17-related cytokines [40].
A recent in vivo study observed an increased frequency of circulating Th17 and 
Tc17 cells, accompanied by increased serum levels of IL-17 in remission RRMS 
patients treated with IFN-β [41]. This contradiction underlines the need to clarify 
the role of the IL-17-producing T cells in RRMS patients.
It has been demonstrated that a significant proportion of Th17 cells convert into 
IFN-γ-producing T cells and have chemokine receptors from both Th17 and Th1 
subtypes, referred as Th17.1 cells. The enhanced potential of Th17.1 cells to infiltrate 
the CNS was supported by their predominance in CSF of early MS patients and 
their preferential transmigration across human brain endothelial layers [42, 43]. 
In remission RRMS patients, it was observed that Th17 and Tc17 cells exhibited a 
higher degree of Th1 plasticity since there were higher frequencies of those cells 
simultaneously producing intracellular IL-17 and IL-2 or IFNγ or TNFα [41].
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Another subset of T cells, the Tregs, are characterized by high expression of 
CD25 and the transcription factor Foxp3, which is critical for their development, 
lineage commitment, and regulatory functions. Tregs are a very heterogeneous 
population with suppressive functions that maintain tolerance to harmless food/
self-antigens and prevent autoimmune disease. Numerous studies have identified 
Tregs as important immunoregulators in many inflammatory and autoimmune 
disease conditions including asthma, MS, and type-I diabetes [37, 44].
In MS patients, both reduced or normal frequency of Tregs was observed. Libera 
et al. described a significant decrease in Treg cells in remission RRMS patients [45]. 
Haas et al. state that the frequency of Treg cells was normal in MS patients but with 
a lower suppressive function on autoreactive T cells [46]. Venken et al. described 
that RRMS patients treated with IFN-β showed restored naive Treg numbers as 
compared with age- and disease-duration-matched untreated patients [47].
Recently identified, the Tfh subset expresses the chemokine receptor CXCR5 
as well as CD279 [48], is specialized in helping B cells to produce antibodies in the 
face of antigenic challenge and plays a crucial role in orchestrating the humoral 
arm of adaptive immune responses. Tfh cells have the unique ability to migrate into 
follicles in secondary lymphoid organs where they colocalize with B cells to deliver 
contact-dependent and soluble signals that support survival and differentiation of 
the latter cells. There is no complete and thorough understanding of how naïve Th 
cells differentiate into mature Tfh [49, 50].
Tfh cell levels are elevated in the blood of MS patients and this population is 
positively correlated with the progression of disability. One potential mechanism 
through which Tfh cells can contribute to disease is promoting the inflamma-
tory B-cell activities, suggesting that Tfh cells cooperate with Th17 cells to induce 
inflammatory B cell responses in the CNS and increase disease severity [49].
The increased frequencies of Th1 cells, activated Tfh- and B-cells parallel find-
ings from pathology studies, along with the correlation between activated Tfh- and 
B-cells, suggest a pathogenic role of systemic inflammation in progressive MS [51].
A similar frequency of Tfh cells between RRMS patients and healthy subjects 
was reported. However, this subset tend to exhibit a more proinflammatory activ-
ity, since higher frequencies of TNF-α+ Tfh cells have been observed [41]. It is well 
known that Tfh cells play an important role in T/B interactions in germinal centres 
(GC) and one potential mechanism through which Tfh cells can contribute to MS is 
in promoting inflammatory B-cell activities [49]. The Tfh subset and others follicu-
lar like T cells subsets, like Treg/follicular cells, are promising targets in the study of 
T cells in pathophysiology of MS.
4.2.2 γδ T cells
γδ T cells develop in the thymus together with αβ T cells but rearrange a different 
TCR, consisting of a TCR-γ and TCR-δ chain. One of the most striking characteris-
tics of γδ T cells is their inherent ability to secrete pro-inflammatory cytokines very 
rapidly, which influences adaptive immunity, they carry out immediate effector 
functions as well as mounting a memory response upon microbial reinfection. This 
fast response can be explained by γδ T cells exiting the thymus already with the 
functional competence to produce cytokines with no need of APCs cells [52, 53].
In MS, their potential importance is increased by the finding that γδ T cells 
accumulate in demyelinating CNS MS plaques; these cells show evidence of oligo-
clonal expansion indicating a local response to currently unknown antigens. γδ T 
cells have been shown to be present in both MS lesions and in CSF, and sequencing 
studies have shown that the major γδ T subsets present in the lesion differ from 
those in the CSF, suggesting specific functions for these cells in lesion development. 
Neuroimmunology
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In more chronic lesions, γδ T cells may become the most prevalent type of T cell in 
the lesion. γδ T cells isolated from the CNS can be expanded but only in patients 
with relapse disease, not chronic MS patients, suggesting that these cells may have 
differential roles during various phases of the disease [54, 55].
The frequency, the migratory pattern, the activation status of γδ T cells in 
RRMS patients are unclear. Between remission and relapse RRMS patients, the γδ 
terminally differentiated effector memory T cells (TEMRA) and the CCR5
+ γδ TEMRA 
decrease in relapse when compared with remission RRMS patients [56], constitut-
ing a good biomarker between phases of the disease. Probably as a result of the 
migratory pattern describe for this phase of MS, preferentially toward RANTES and 
MIP-1α, whose expression is increased during relapses [57, 58].
The decrease of Eomesodermin and granzyme B mRNA expression in CD27− γδ 
T cells suggests a reduction in the cytotoxic potential of the circulating pool of γδ T 
cells, particularly in relapsing RRMS patients [56].
4.3 B lymphocytes
The most consistent immunodiagnostic feature and hallmark immunologic find-
ing in MS patients is the presence of oligoclonal bands (OCB) in the CSF and their 
absence in peripheral circulation. Consequently, the pathogenic function of B cells 
in MS has been traditionally associated with antibody production. However, B cells 
have three putative biological roles: production of proinflammatory or regulatory 
cytokines, function as APCs and antibody production [59].
In MS, the memory B cells, plasmablasts and plasma cells preferentially cross 
the BBB and migrate into the CNS, where they dominate the B cell pool and exert 
different effector functions. B cells seem to be abnormally polarized toward a more 
proinflammatory phenotype [60].
More recent, somatic hypermutation studies have demonstrated that identical B cell 
clones can be shared between the CNS and the periphery in individual patients. These 
studies provide evidence of bidirectional trafficking of distinct B cell clones (both into 
and out of the CNS). The patterns suggest that B cells can travel back and forth across 
the BBB and commonly re-enter GC (in the meninges or cervical lymph nodes) to 
undergo further somatic hypermutations. These findings change our view of lympho-
cytic surveillance of CNS tissue and underline that B-cell trafficking is an important 
topic for future research and therapy strategies [60–62]. This news about recirculation 
of B cells through the BBB alters the perception of the role of B cells in MS.
B cells are released in the peripheral blood, recirculate between the secondary 
lymphoid tissues, and dying after a few days. According to phenotypic profile of B 
cell subsets, which also reflects their functional abilities and behavior, four major 
maturation-associated subsets can be identified in the human peripheral blood: 
immature/transitional, naive, memory and plasmablast [63].
In remission RRMS patients submitted to IFN-β, the percentage of immature/
transitional B cells increases. This increase can be seen as an attempt to increase 
anti-inflammatory cytokines. Meanwhile, a decrease in the proportion of circulat-
ing class-switched memory B cells was reported [64, 65].
The relapsing RRMS patients exhibited distinct changes in B cell subsets homeo-
stasis, resulting in a decrease in the total population of B cells, including a decrease 
of the immature/transitional and naïve B cell subsets when compared with remis-
sion RRMS patients. On the other hand, the plasmablast B cell subset presented an 
increase in relapse RRMS patients. The ratio between immature/transitional B cells 
and plasmablasts can thus be considered as a potential biomarker between phases of 
RRMS patients. The remission RRMS patients and the healthy subjects presented a 
similar ratio, and the relapse RRMS patients present a decreased ratio [66].
9
Peripheral Biomarkers in Multiple Sclerosis Patients Treated with Interferon-Beta
DOI: http://dx.doi.org/10.5772/intechopen.99006
According to the new and recent data about the recirculation of B cells in RRMS, 
it seems that the increase of plasmablasts in circulation of relapsing episodes may 
be due to a migration of these cells from cervical lymph nodes and/or from B cell 
aggregates described in the meninges of MS patients to the blood marrow in an 
attempt to promote the immune response [67].
5. Effects of IFN-β in circulating cells
An ever-expanding body of literature, sometimes difficult to integrate, defines 
the intricate pathways by which IFN-β mediates its broad effects. To resume the 
effects of IFN-β in circulating immune cells a table listing the relevant studies and 





• reduces mDCs frequency, pDCs frequency remains unchanged, mDCs/pDCs ratio 
decreases [23, 25, 65];
• activated pDCs decreased TLR9 consequently decreases Th1 cell differentiation, 
reduced pro-inflammatory IL-6, TNF-α, IFNγ secretion, expression of CCR7 and 
increased IL-10 secretion [23–26, 66]
• activated status mDCs trough the expression of HLA-DR and mRNA gene expression 
of CX3CR1 reducing their migration pattern [25]
• pDCs showed reduced expression of the maturation markers CD83 and CD86 molecules 
and lower secretion of proinflammatory cytokines, including IFN-α, and a decreased 
ability to stimulate allogeneic T cells in response to maturation stimuli [22, 65];
• enhances HLA-DR expression in circulating monocytes [25, 30]
T cells • reduces T-cell activation, downregulating MHC class II and costimulatory molecules, 
prevents the interaction of B7/CD28 and CD40/CD40L decreases the activation of 
myelin-reactive T cells [4, 5, 23];
• inhibits proinflammatory IFNγ, TNFα and IL-17, increasing the production of IL-10 
[5, 68];
• increases levels of Th1 cytokines during RRMS relapse, whereas Th2 cytokines 
increases during remission in RRMS patients [5, 23, 40];
• prevents T-cell adhesion and extravasation across the BBB [4, 5];
• induces Treg cells [4, 5, 20];
• Mediates the chemokine receptor CCR7, channel autoreactive T cells into secondary 
lymphoid tissue rather than to CNS [5];
• the CCR5+γδ TEMRA cells decreases with a reduction in the cytotoxic potential in relapse 
when compared to remission [56]
B cells • induces expression of the B-cell survival factor B-cell-activating factor, with a shift 
toward less mature circulating B cells [65];
• reduces of memory B cell frequency exerted by the induction of a FAS-R-mediated 
caspase 3-dependent apoptosis [16];
• downregulates costimulatory molecules, CD40 and CD80 becoming less efficient 
APCs and less able to induce T-cell proliferation [21];
• inhibits proinflammatory cytokines, IL-1β and IL-23, anti-inflammatory IL-10 is 
upregulated in B cells [22, 64];
• the ratio between immature/transitional B cells and plasmablasts decreases in relapse 
when compared to remission RRMS [66]
Table 1. 
Main effects of IFN-β in circulating immune cells in MS.
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A major role for IFN-β is the induction of a priming state through which produc-
tion and regulation of mediators, including cytokines, are affected by synergistic 
or antagonistic interactions. In the treatment of MS, the most important IFN-β 
mechanisms of action appear to be mediated mainly by the increased expression 
and concentration of anti-inflammatory agents, in turn, down-regulating the 
inflammatory state observed in the patients both in the periphery and in the brain 
tissue (Figure 1) [21].
6. Methodology
The work from our group started with the selection of the RRMS patients 
and collected blood from each one after assigned an informed consent. By flow 
cytometry performed direct immunofluorescence membrane and intracytoplasmic 
staining protocols to identify and characterize the circulating subsets. To functional 
assessment of the cells was measured intracellular cytokines at single cell level, after 
in vitro stimulation. To evaluation of gene expression, RNA isolation and quantita-
tive real-time reverse transcriptase-polymerase chain reaction was performed.
In our group publications, one can be find the flow strategy with the description 
of the antibodies used and the mRNA gene expression studies performed in APCs 
[25], in T cell subsets [41], in γδ T cells [56] and in B cell subsets [66].
The literature search was performed using the PubMed electronic bibliographic 
database. The search was restricted to English and publications between 2010 and 
2021. The keywords used were: multiple sclerosis, IFN-β, antigen presenting cells, T 
cells and B cells alone or in conjugation. The bibliographies of retrieved articles and 
previous review articles were hand searched to obtain additional articles.
Figure 1. 
Main effects of IFN-β in RRMS patients (a) remission phase and (B) relapse phase. mDC – Myeloid dendtitic, 
pDC – Plasmacytoid dendtitic cell, cMO – Classical monocytes, iMo – Intermediate monocytes, ncMo – Non-
classical monocytes.
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7. Conclusion
In demyelinating diseases, mainly in relapse phase of RRMS, the BBB suffer a 
profound disturbance, so as the exchanges and ultimately the CNS itself. Despite 
CNS suffered an immune response, immune abnormalities could be found in the 
peripheral immune compartment.
The periphery assumes an extremely important role in the study of MS. In 
remission phase is establish an equilibrium between CNS and systemic circulation. 
In this chapter we have attempted to contribute to highlight the more relevant data 
regarding circulating cell subsets that could potentially be considered as peripheral 
biomarkers in RRMS patients treated with IFN-β.
Some circulating immune cells assume differences between the remission and 
relapse phases of RRMS. These differences may be used as disease activity biomark-
ers to measure inflammatory and/or neurodegenerative components of disease and 
helpful to discriminate between phases of RRMS.
Technological advances of flow cytometry have greatly increased the strength 
of analysis achievable at the single-cell level. These developments can be applied 
to understand more clearly the immunopathology of MS and the identification of 
consistent, safe and reproducible biomarkers in the periphery.
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